



महामना पंडित मदन मोहन मालवीय कैंसर केंद्र एवं होमी भाभा कैंसर अस्पताल
MAHAMANA PANDIT MADAN MOHAN MALAVIYA CANCER CENTRE
& HOMI BHABHA CANCER HOSPITAL

(टाटा स्मारक केंद्र की इकाईयां / Units of TATA MEMORIAL CENTRE)
परमाणु ऊर्जा विभाग, भारत सरकार / DEPT. OF ATOMIC ENERGY, GOVT. OF INDIA
वाराणसी, उत्तर प्रदेश – २२१००५ / VARANASI, UTTAR PRADESH – 221005



Advt. No. HBCH/MPMMCC/PROJECT/2025/30

Date: 15.07.2025

WALK-IN INTERVIEW

Reporting time: 09:00 A.M. to 10:00 A.M.
(Project based vacancies)

Eligible and interested candidates are invited to attend the Walk-In Interview at Mahamana Pandit Madan Mohan Malviya Cancer Centre, Sunder Bagiya, B.H.U Campus, Varanasi, Uttar Pradesh – 221005. Candidates must bring Bio-data (Resume), Recent passport size photograph, PAN card, Aadhar card, Educational Certificates, Experience certificates in original and one set of self-attested copies, on the interview date(s).

(1)	Name of Post	Project Nurse-III
	No. of Vacancy	01 (one)
	Walk-In Interview Date	Monday, 21st July 2025
	Monthly Remuneration:	Rs. 33,600/-
	Eligibility Criteria	Basic or Post Basic B.Sc. (Nursing) recognized by Indian Nursing Council/ State Nursing Council. Candidates should be eligible to register with the Indian Nursing Council / State Nursing Council. 1 year's clinical experience is desirable.
	Project Name & A/c No.	Comprehensive Genomic Profiling of Recurrent / Metastatic Oral Cancer for Personalized Treatment: A Novel Approach to Improve Clinical Outcomes and Affordability (Project A/c No.160048)
(2)	Name of Post	Clinical Trial Coordinator
	No. of Vacancy	02 (two)
	Walk-In Interview Date	Monday, 21st July 2025
	Monthly Remuneration:	Rs. 25,000/- to Rs. 44,000/-
	Eligibility Criteria	Graduate degree in science with PG Diploma in Clinical Research. Experience of one year in relevant filed is desirable.
	Project Name & A/c No.	(i) A Multicenter, Double-blind, Randomized, Parallel-group, Phase 3 Study to Compare the Efficacy and Safety of the Proposed Biosimilar PERT-IJS and EU-Perjta® along with Trastuzumab and Chemotherapy (Carboplatin and Doctaxel) as Neoadjuvant Treatment in Patients with Hormone Receptor Negative (HR-ve) Human Epidermal Growth Factor Receptor 2 (HER2)-positive Early Stage or Locally Advanced Breast Cancer (Project A/c No. 160020) (ii) TACTI-004, a double-blinded, randomized Phase 3 trial in patients with advanced/ metastatic non-small cell lung cancer (NSCLC) receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (PD-1 Aantagonist) and chemotherapy (Project A/c No. 160049)

Note:

1. The tenure will be valid for six months and may be extended further based on satisfactory performance and the institute's requirement.
2. If there are many applicants, a written test will be conducted as a shortlisting criterion, and only eligible candidates will be invited for the interview accordingly.
3. Outstation candidates are advised that accommodation will not be provided.

(Piyush Tripathi)
Administrative Officer III (HRD)